|
|
 |
|
Viewing report
|
|
|
|
Switzerland Pharmaceuticals and Healthcare Report Q3 2008
Business Monitor International, Sep 2008, Pages: 67
The Switzerland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Switzerland's pharmaceuticals and healthcare industry.
Switzerland’s drug market growth was strong in 2007, following a couple of year’s worth of second-rate performance. Indeed, last year saw the market outperforming the European average, in particular its Western European counterparts. Much of this improved performance has been down to a strong pace for high price patented growth, after two years where lower-priced generics ate into overall market share. Total drug expenditure should continue to show robust growth, reaching a value of CHF6.47bn (US$5.17bn) in 2012. This will be driven by growth in all markets, with generics continuing to gain market share, albeit at a slower rate than in recent years. The Swiss biotechnology sector also performed well in 2007, attracting record levels of investment and healthy revenue growth.
Nevertheless profitability remains a lingering problem many biotech firms, a fact from which Swiss firms are not exempt, and there have been cumulative losses for the industry. The last quarter was dominated by acquisitions and divestments in terms of company activity. The highlights of these were Novartis’ US$11bn investment in optalmic group Alcon and US$400mn acquisition of US antibiotic developer Protez Pharmaceuticals. Meanwhile Nycomed decided to divest in its oncology pipeline in order to focus on its main therapeutic areas, including gastroenterology and pain management. The deal will see German firm 4SC take on development of the oncology candidates. The most recent addition to BMI’s reports – the Burden of Disease Database (BoDD) – has highlighted Switzerland as one of the healthiest countries in Europe. The country ranks fourth among Western European countries least burdened by disease.
Like many of Europe’s more developed states, the leading causes of disability-adjusted life years (DALYs) are neuropsychiatric conditions, cancer and cardiovascular diseases. Switzerland remains top of the pile in BMI’s Business Environment Rankings for Western Europe. Despite being a relatively small market, Switzerland’s high per capita spending and strong growth means the country scores well, and the country draws on its transparent regulatory environment, strong economy and stable political outlook as its major strengths.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Switzerland Pharmaceuticals and Healthcare Report Q2 2008
Switzerland Pharmaceuticals and Healthcare Report Q1 2009
Switzerland Pharmaceuticals and Healthcare Report Q4 2009
Switzerland Pharmaceuticals and Healthcare Report Q3 2007
Pharmaceutical Product Lifecycle Management Forecast in Western Europe 2006-2012 (Databook)
Switzerland Pharmaceuticals and Healthcare Report Q4 2008
The Pharmaceutical Market: Switzerland
The Outlook for Pharmaceuticals in Western Europe
Kuwait Pharmaceuticals and Healthcare Report Q3 2008
South Africa Pharmaceuticals and Healthcare Report Q3 2008
Tissues in Switzerland
Wipes in Switzerland
|
|
|
|
